Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 3, 2012, Pages 296-302

  Tunn, U W ^a   Canepa, G ^b   Kochanowsky, A ^c   Kienle, E ^d  

^a Klinikum Offenbach GmbH   (Germany)

^b GALLIERA HOSPITAL   (Italy)

^c Urological Practice   (Germany)

^d Medical Consultant ^*  (Germany)

Author keywords

intermittent androgen deprivation; leuprorelin acetate; testosterone recovery

Indexed keywords

LEUPRORELIN; TESTOSTERONE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84865327146     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.12     Document Type: Article

References (21)

1. Heidenreich A, Bolla M, Joniau S, Van der Kwast JH, Matveev VB, Mason MD et al. Guidelines on prostate cancer. Eur Assoc Urol 2010. http://www.uroweb. org/gls/pdf/Prostate%20Cancer%202010%20June%2017th.pdf.
2. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993; 71: 2782-2790.
3. Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: Clinical experience and practical applications. Urol Clin North Am 2006; 33: 167-179.
4. Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 2007; 100: 738-743.
5. Spry NA, Galvao DA, Davies R, La Bianca S, Joseph D, Davidson A et al. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: Results of a 33-month observational study. BJU Int 2009; 104: 806-812.
6. Calais da Silva FC, Bono AV, Whelan P, Brausi M, Queimadelos AM, Martin JAP et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase III study of the South European Uroncological Group. Eur Urol 2009; 55: 1269-1277.
7. German Society of Urology. Interdisciplinary S3 guideline of quality for early detection, diagnosis and treatment of various stages of prostate cancer. 2009. http//www.uro-freiburg.de/S3-Leitlinie-Prostatakarzinom-2009,102.html.
8. Bong GW, Clarke Jr HS, Hancock WC, Keane TE. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology 2007; 71: 1177-1180.
9. Gulley JL, Figg WD, Steinberg SM, Carter J, Hussain MH, Dahut WL. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005; 173: 1567-1571.
10. Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS et al. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2008; 180: 1432-1436.
11. Gleave M, Klotz L, Taneja SS. The continued debate: Intermittent vs continuous hormonal ablation for metastatic prostate cancer. Urol Oncol 2009; 27: 81-86.
12. Tunn UW. Can intermittent hormone therapy fulfill its promise? Eur Urol 2008; (Suppl 7): 752-757.
13. Tunn UW, Canepa G, Hillger H, Fuchs W. Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy-final result of a european randomized prospective phase-III clinical trial AUO study AP 06/95, ED 507. J Urol 2007; 177: 201 (abstr. 600).
14. Tunn UW. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: Putting IAD under the spotlight. BJU Int 2007; 99: 19-22.
15. Bostwick DG. Staging prostate cancer-1997: Current methods and limitations. Eur Urol 1997; 32(Suppl 3): 2-14.
16. Tunn UW. Intermittent endocrine therapy of prostate cancer. Eur Urol 1996; 30 (Suppl 1): 22-25.
17. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinber SM et al. A randomized phase II trial of thalidomide an angiogenesis inhibitor in patients with androgen-independent prostate cancer. Clin Cancer Res 2001; 7: 1888-1983.
18. Figg WD, Hussain MH, Gulley JL, Arien PM, Aragon-Ching JB, Petrylak DP et al. A double-blind randomized crossover study of oral Thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol 2009; 181: 1104-1113.
19. Oefelein M. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: A phase I assessment. Urology 1999; 54: 694-699.
20. Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006; 42: 1083-1092.
21. Klotz L, O'Callaghan CJ, Ding K, Dearnaley DP, Higano CS, Horwitz EM et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol 2011; 29(Suppl 7): (abstr 3).